Mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs) have shown promising efficacy as a cell therapy. Ross Macdonald, PhD, Cynata Therapeutics, Melbourne, Australia, discusses results from a Phase I trial (NCT02923375) assessing CYP-001, a MSC-based cell therapy in patients with steroid resistant graft-versus-host disease (GvHD). For patients who progress from corticosteroids, treatment options remain poor and mortality remains high. CYP-001 resulted in a complete response in over half of the cohort and after a two year follow-up, a survival rate of over 50% was reported. This interview was conducted during Meeting on the Mediterranean 2022.